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Abstract: (1) Objective: The purpose was to analyze the effectiveness of myofascial therapy on mus-
culoskeletal pain and functionality of the upper extremities in female breast cancer survivors, and to
evaluate the changes in range of motion, quality of life, and mood state of these patients. (2) Methods:
Systematic searches were performed on the MEDLINE/PubMed, Web of Science, Scopus, and Physio-
therapy Evidence Databases for articles published until October 2020, in order to identify randomized
controlled trials which analyzed the effectiveness of myofascial therapy as compared to a control group,
passive treatment, placebo, or another intervention, and allowed co-interventions on female breast
cancer survivors. Two reviewers examined the sources individually, calculated the risk of bias and
extracted the data (PROSPERO number CRD42020215823). (3) Results: A total of eight RCTs were
included. The results suggested that myofascial therapy does not have a greater statistically signifi-
cant immediate effect on pain intensity (SMD: −0.15; 95% CI −0.48, 0.19), functionality (SMD: −0.17;
95% CI −0.43, 0.09) and range of motion in flexion (SMD: 0.30; 95% CI −0.13, 0.74) than an inactive,
passive treatment or another intervention. However, a statistically significant result was observed for
the abduction shoulder in favor of the experimental group (SMD: 0.46; 95% CI 0.05, 0.87; p = 0.03).
(4) Conclusion: In general, although we found greater overall effects in support of the intervention with
myofascial therapy than other control groups/types of interventions, the subgroup analysis revealed
inconsistent results supporting myofascial therapy applied to breast cancer survivors.
Keywords: breast cancer; myofascial release; functionality; pain; quality of life; range of motion
1. Introduction
Of the 18.1 million cases of cancer globally diagnosed [1], breast cancer accounts
for 11.6%, being the most common cancer among women [2,3]. In Spain, this incidence
increases to 28.7%, and one in eight women is at risk of developing breast cancer [4]. The
rising incidence of breast cancer in developed countries is mainly due to demographic
factors, lifestyle, and reproduction rates [5]. Despite this high incidence, thanks to de-
velopments in early detection techniques, as well as rapid implementation of treatment
protocols [6], its survival rate is over 90% [7].
Treatment of breast cancer generally involves a combination of different methods, and
may produce toxicities, which can be cumulative and difficult to separate clinically, includ-
ing surgery, radiation, chemotherapy, hormonal therapy, and/or targeted therapy [8,9].
Surgical treatment for breast cancer includes breast-conserving surgery, combined with ra-
diation, or mastectomy with or without radiation and with or without immediate/deferred
reconstruction [9]. Breast-conserving therapy, consisting of breast-conserving surgery
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(lumpectomy) plus radiation, is the standard treatment for most women with stage I and
II breast carcinomas [10]. However, all survivors are at risk of suffering from side effects
of treatment in the short- or long-term, such as hemorrhage, infection at the surgical site,
weakness in the arm or shoulder, restricted movement, swelling, numbness, pain, and
lymphedema [11–15].
Radiation therapy is an adjuvant therapy that is used in 50% of patients, which may
lead to fibrosis in the adjacent tissue [8]. Radiation-induced fibrosis is a form of damage
to normal tissues after radiation therapy. It can affect the underlying fascia, muscles,
organs, and bones on both the affected and unaffected sides, cause persistent symptoms
and aesthetic disfigurement, thereby affecting quality of life [16–19].
Furthermore, the dissection of the axillary lymph nodes, the radiation on the regional
lymph nodes and the patient’s preoperative body mass index, among others, are considered
to be factors that contribute to the development of one of the most frequent side effects
of breast cancer: lymphedema [20]. The risk of getting lymphedema after overcoming
cancer is between 6% and 45% [21–24] and, of these cases, 90% arise between 18 and
24 months after treatment [20,25]. Additionally, lymphedema is associated with other
symptoms, such as pain, bloating, pressure, fatigue, limited joint movement, mainly in the
abduction of the shoulder and elbow bending, and the subsequent reduction in use of the
affected limb [22,26]. Conversely, postoperative pain is another side effect which occurs
in at least half of women who have undergone surgery between 6–15 months after the
operation [27,28]. The prevalence of neuropathic pain is 24% nine months after surgery [28].
While improvement in diagnostic processes and in the choices available for medical
treatment to reduce possible long-term effects have led to a higher survival rate after breast
cancer diagnosis, new challenges have arisen in addressing these effects in healthcare
systems [29]. There are several studies which suggest the use of physical therapy to
treat side effects of breast cancer following medical treatment. Among the most highly-
recommended therapies are mobilization, active exercises or active-assisted exercises, and
manual therapy [30–32]. Myofascial release is found under the scope of manual therapy,
and is a low-impact, long-term treatment with the aim of restoring the length of the fascia,
eliminating functional limitations and reducing the perception of pain to improve the
function of the locomotor system [33]. Numerous clinical trials have demonstrated the
benefits of myofascial therapy on different populations, showing an improvement in range
of motion and a decrease in perceived pain [34–37]. However, to date, no systematic
reviews nor meta-analyses have been carried out about the effects of myofascial therapy
on the treatment of the side effects derived from the medical treatment of breast cancer,
whereas because of its characteristics as a manual therapy specialty as well as the absence
of secondary side-effects after its use [33], it seems an adequate technique to manage with
breast cancer survivors’ impairments.
Thus, the objective of this study is to perform a systematic review, together with a
meta-analysis, to check the effects of myofascial therapy on female breast cancer survivors’
pain, functionality, joint range of motion, and mood state. We hypothesize that myofascial
release is an adequate approach to improve these factors.
2. Materials and Methods
2.1. Protocol and Registry
A systematic review and meta-analysis was carried out, taking into account the items
on the recent declaration of ‘preferred reporting items for systematic reviews and meta-
analyses’ (PRISMA) [38]. Systematic review registration: http://www.crd.york.ac.uk/
PROSPERO (accessed on 21 April 2021). PROSPERO registration number: CRD42020215823
(23 November 2020).
2.2. Search and Information Sources
The bibliographic search was performed during the months of March through Octo-
ber 2020 on the Medline (through the platform PubMed), Scopus, Web of Science, and PEDro
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databases. The search strategy was based on terms registered on the MeSH list (“breast”,
“cancer”, and “myofascial”) combined with the Boolean operator (AND), adapted to the
characteristics of each database. Any duplicates that were identified in the multiple database
searches were removed. Additionally, the reference lists for the included studies were also ex-
amined and experts in the field were contacted (for example, authors of the included studies)
to obtain additional information or information which was not implicit in the published trials.
2.3. Inclusion and Exclusion Criteria
The inclusion and exclusion criteria were defined using the PICO process [39] (Patient,
Problem or Population, Intervention, Comparison, Control or Comparator, Outcome(s)).
2.3.1. Types of Studies
Randomized controlled clinical trials (RCTs) were included. Quasi-experimental con-
trolled trials were excluded. In addition, the following inclusion criteria were taken into
account: RCTs published in the last 20 years (from 2000 onwards), written in English, avail-
able in full-text version, focused on the ongoing effects of breast cancer intervention with
myofascial techniques. All studies that did not meet these characteristics were excluded.
2.3.2. Types of Participants
Studies with female subjects who had completed breast cancer treatment at least two
months prior and had upper limb or neck pain. An exception was made with one of the
studies, which was related to palliative care, but was included, as the same aspects were
assessed as in the other studies. The age of participants and tumor location were not
considered as criteria.
2.3.3. Types of Interventions
Studies were included in which side effects derived from breast cancer treatment
were treated with myofascial therapy. Studies that treated these effects with myofascial
therapy accompanied by other manual or physical therapies were not excluded, nor were
studies restricted by the duration of treatment, frequency or type of techniques applied
in the treatment. Studies comparing myofascial therapy with any other intervention or
no intervention were included. We also included any study which compared myofascial
therapy accompanied by other therapies, with only the application of those other therapies.
All habitual medication was allowed to be taken during the studies.
2.3.4. Types of Outcome Measures
Studies that evaluated one or both of the following aspects as primary measures
were chosen: pain and functionality of the shoulder affected. For pain, the studies should
have used the Visual Analogue Scale (VAS), or a comparable numerical scale, and in the
evaluation of functionality, the Disabilities of the Arm, Shoulder and Hand (DASH), or
scale should have been used. As a secondary outcome measure, the following were also
taken into consideration: the evaluation of shoulder mobility using goniometry; the mood
state of the participants evaluated, for example, with the Profile of Mood States (POMS)
scale; and quality of life measured using the Health Questionnaire SF-36. The results
were collected in three specific time periods: immediately following treatment, short-term
(≤3 months), medium-term (between six and nine months), and long-term (≥12 months).
2.4. Study Selection
Two reviewers (I.C.L.-P., M.M.C.-P.) used the pre-specified criteria to select relevant
titles, abstracts and full articles. An article was deleted if it was determined that it did
not meet the inclusion criteria. If there were any hesitations about the selection decisions,
a third reviewer (A.M.C.-S.) was consulted. Once the review was completed, the search
strategy was repeated, in case any new studies had been published, and they were analyzed
to assess their inclusion. The last search was carried out in November 2020.
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2.5. Data Extraction and Management
Firstly, the titles and abstracts of the references retrieved from the searches were
selected. The full text was obtained for references which the authors considered potentially
relevant. Full-text references were then independently evaluated for inclusion according to
the inclusion criteria for considering studies for this review.
To manage the data, a data summary sheet was created, based on the Cochrane
recommendations. The data extracted were: author and year, type of study, number and
type of patients, type of intervention, number and duration of treatment sessions, outcome
measures, and primary outcomes found among groups. If key information was missing
from the study report, the authors of the report were contacted to obtain this information.
2.6. Risk of Bias Assessment
We used the recommendations from the Cochrane Collaboration to evaluate the risk
of bias for all of the articles. Each item was evaluated with the objective of discerning
whether the trials eligible for inclusion in this review were valid enough for their results
to be interpreted. The items evaluated were: specification of selection criteria, random
sequence generation, homogeneity among groups, allocation concealment, blinding of
participants and personnel, blinding of the outcome assessors, incomplete outcome data,
selective reports, and other biases.
Two reviewers (I.C.L.-P., L.O.-C.) independently assessed the risk of bias for each of
the articles selected for the current study. An arbitrator (A.M.C.-S.) was consulted to settle
any disagreements.
Each item was classified as “high risk”, “low risk”, or “unclear risk” of bias. A sensitivity
analysis was performed on the primary results to explore the effects of including and excluding
trials with a high risk of bias (sensitivity analysis).
2.7. Statistical Analysis
A heterogeneity analysis of the selected studies was performed. In terms of continuous
data and dichotomous data, effect sizes were measured using standardized mean difference
(SMD) and 95% confidence interval (CI), or risk ratio (RR) with 95% CI, respectively.
Heterogeneity within RCTs was examined using the I2 test, considering I2 ≥ 50% as a sign of
substantial heterogeneity. Once there were >2 homogeneous studies, RevMan 5.4 (Cochran
Collaboration, London, UK) software was used to perform meta-analyses. Sensitivity
analyses were conducted for the robustness of the result of meta-analyses.
3. Results
3.1. Selection of Studies
The initial search retrieved 181 potential articles, of which 112 were excluded after
reviewing their titles and abstracts, and 27 were duplicates, leaving 42 full-text articles to be
reviewed. After the application of the inclusion and exclusion criteria, 34 of these articles
were eliminated, leaving eight studies for this systematic review and meta-analysis. Figure 1
illustrates the different phases of the review, using the eligibility and data-synthesis PRISMA
flow diagram.
3.2. Characteristics of Studies Included
Eight RCTs were included, with a total of 333 participants [40–47]. The study devel-
oped by Fernández-Lao et al., divided into two publications [40,41] contained the smallest
sample-size, with 20 participants; whereas the one with the largest sample size was the
study by Groef et al. [42] with 147 participants.
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All of the studies reported the place of recruitment and methods used. The study devel-
oped by Fernández-Lao et al. were was performed on patients from the Oncological Unit 
at the Virgen de las Nieves Hospital in Granada, Spain [40,41]; one at the University of 
Granada [43]; one in Valencia, Spain, at the Spanish Association Against Cancer (AECC) 
[44]; three at the University Hospital in Leuven, Belgium [42,45,46]; and in the study car-
ried out in the United States, the women interested in taking part in the study contacted 
fl
Regarding the location where the studies took place, three were performed in
Spain [40,41,43,44], three in Belgium [42,45,46] and another in the Midwestern United States [46].
All of the studies reported the place of recruitment and methods used. The study developed
by Fernández-Lao et al. were was performed on patients from the Oncological Unit at the
Virgen de las Nieves Hospital in Granada, Spain [40,41]; one at the University of Granada [43];
one in Valencia, Spain, at the Spanish Association Against Cancer (AECC) [44]; three at
the University Hospital in Leuven, Belgium [42,45,46]; and in the study carried out in the
United States, the women interested in taking part in the study contacted the coordinator to
participate [47]. Table 1 shows the main characteristics of each of the studies.
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Cancer Therapy for breast cancer patients. * These publications belong to the same study, but evaluate different outcomes.
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3.3. Characteristics of the Participants
All of the studies contained participants diagnosed with breast cancer. No distinction
or mention of race is made in any study. The age of the patients was detailed in all of the
studies, ranging from 21–65 years old [40–47]. In addition, the stage of patients’ cancer was
considered as inclusion criteria by Fernández-Lao et al., and was their study was carried
out on subjects with cancer in stages I-IIIA [40,41]. Only the study by Serra-Añó et al. [44]
considered the type of surgery the patients had undergone (only conservative/partial)
when choosing study participants.
3.4. Characteristics of the Interventions
All of the studies had two comparison branches. The studies compared myofascial
therapy with: educational sessions on healthy lifestyles, focusing on nutrition, relaxation
techniques, and exercise, with advice on how to improve quality of life after cancer [40,41],
with a standard physical therapy program and consistent placebo intervention with bilat-
eral static hand placements on the upper body and arm [42,45,46], with pulsed shortwave
therapy [43], and with relaxing Swedish massage which avoided the affected area [47].
The types of myofascial interventions used, although all of them were manual inter-
ventions, varied among the studies. A myofascial induction protocol centered on the neck
and shoulder following the Barnes approach [40,41], trigger point treatments on upper
limbs and adhesions in the pectoral muscle, cervical region, diaphragm, and scars [42,45,46],
myofascial massage specific to the chest, thorax, and shoulder of the affected side [46], and
myofascial release [43,44] were all used.
With regard to the number and length of sessions and the duration of the therapy, the
studies were very heterogeneous. Fernández-Lao et al. conducted two 40-min sessions
separated by an interval of two and three weeks [40,41], two studies conducted two 30-min
sessions per week for eight weeks [42,47] two conducted two 30-min sessions per week
for 12 weeks, later reduced to one session per week [45,46], one a 50-min session per week
for four weeks [44], and finally, one study conducted two 30-min sessions four weeks
apart [43] (see Table 2).
3.5. Outcome Measures
3.5.1. Primary Measures
Pain: All but one of the studies evaluated pain or pain-related outcomes [41]. In the
majority of cases, it was measured using a visual analog scale (VAS) [42–45,47]; in two of
the studies, quantitative and qualitative aspects of pain were assessed using the McGill
Pain Questionnaire [42,45]. Furthermore, three studies measured pain threshold with
pressure from an algometer on different muscle points [40,42,46]. Pain was assessed using
a scale from 0 to 30 [47], a scale from 0 to 10 [43,44], and a scale from 0 to 100 [42,46]. One
study measured pain in the cervical spine, the affected limb and non-affected limb [43],
and two measured pain in the shoulder, neck region, arm, armpit, trunk side and breast
region [42,46]. The unit of measurement differed between the studies, as one used kPa [40],
and the other two used kg/cm2 [42,46].
Shoulder functionality: the majority of the studies measured functional status using
the Disabilities of the Arm, Shoulder and Hand (DASH) scale [41,43–45]; for all of them,
total scores were 0–100, with a higher score indicating a greater disability. One study
measured shoulder functionality on an unvalidated scale ranging from 0 to 40, where 0 was
no difficulty and 40 was severe difficulty [46].
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Table 2. Intervention characteristics of the Myofascial Therapy Group.
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3.5.2. Secondary Measures
Shoulder mobility: Three studies evaluated shoulder mobility using manual goniom-
etry in degrees [43–45]. One study measured flexion, abduction and active external and
internal rotation on the affected and non-affected side [43]. Another also took into account
extension and adduction but only of the affected side [44], and another measured the
flexion and abduction, and the upward scapular rotation [45].
Mood state: Two studies evaluated the mood states of participants with the Profile of
Mood States (POMS) scale [41,43]. Another study evaluated depression with the Patient-9
Health Questionnaire (PHQ-9), and one study linked participants’ saliva flow rate and
the amount of immunoglobulin A and cortisol to stress levels and the patients’ attitude
towards the intervention.
Quality of life: Five of the eight chosen studies evaluated participants’ quality of
life [42,44–47], although the scales that were used varied among the studies. The most
commonly-used scale was the SF-36 [42,45,46], although one study used the short version,
SF-12 [47], and another one used the Functional Assessment of Cancer Therapy-Breast
(FACT-B + 4) scale.
3.6. Follow-Up
More than half the studies limited their follow-up to immediately following the
intervention [40,41,43,44,47]. Just two studies followed-up between ≥6 months and
≤9 months [45,46] and three studies also followed-up long-term (>9 months) [42,45,46].
3.7. Risk of Bias in the Studies Included
The results of the risk of bias (RoB) analysis for the individual studies are summarized
in Figures 2 and 3. In total, approximately one-third of the studies were considered to have
a moderate RoB.




Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all 
included studies. 
3.8. Effects of the Interventions 
3.8.1. Myofascial Therapy vs. Placebo Treatment or Other Intervention at Post-Immedi-
ate 
Figures 4–7 show the estimated primary effect size (4–8 weeks post-treatment) of the 
intervention with myofascial therapy alone or combined, compared to an inactive control, 
placebo treatment or other intervention with physical therapy for the outcomes of pain 
intensity, functionality, and range of motion in flexion and abduction. 
1. Pain Intensity 
This sub-analysis included four trials [42–45] with 242 participants. No significant 
differences were observed between the effects of myofascial therapy alone or in combina-
tion with a standard physical therapy program and placebo intervention or a standard 
physical therapy program (Figure 4. SMD −0.15, 95% CI −0.48 to 0.19, I2 = 28%). 
2. Functionality 
Meta-analyses of three studies [42,44,46] with 121 participants revealed that there 
were no statistically significant differences between the two groups on post-immediate 
functionality (Figure 5, SMD −0.17, 95% CI −0.43 to 0.09, I2 = 0%). However, the results 
were in favor of the group treated with myofascial therapy. 
3. Range of motion 
This subgroup involved 3 trials [43–45] covering 95 participants. Meta-analysis result 
demonstrated that myofascial therapy does not have a greater statistically significant im-
mediate effect on range of motion in flexion (Figure 6, SMD 0.30, 95% CI −0.13 to 0.74, I2 = 
11%) than a placebo treatment or other intervention. However, a statistically significant 
result was observed for shoulder range of motion in abduction in favor of the experi-
mental group (Figure 7, SMD 0.46, 95% CI 0.05 to 0.87, I2 = 0%; p = 0.03). 
Low-moderate quality evidence indicates that myofascial therapy does not have a 
greater statistically significant immediate effect on pain intensity, functionality, and range 
of motion in flexion than a placebo treatment or other intervention at post-immediate fol-
low up. The estimations of the primary effect show small or null statistically significant 
heterogeneity between the effect size of the studies included in this analysis; the statistic 
I2 ranged from 0% “low threshold” and 28% “low-moderate threshold”. 
Figure 2. Risk of bias graph: revie authors’ judge ents about each risk of bias ite presented as percentages across all
included studies.
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3.8.2. Myofascial Therapy vs. Placebo Treatment or Minimal Intervention at Post-Imme-
diate. 
Figures 8–10 show the results of the estimated primary and secondary effects as for-
est-plots grouped separately by outcome measure type, immediately following the inter-
vention with myofascial techniques. 
1. Pain intensity 
Meta-analyses of two studies [43,44] with 45 participants, demonstrated that the ef-
fect of myofascial therapy was no superior to placebo treatment nor minimal intervention 
for alleviating post-immediate pain intensity (Figure 8, SMD −0.27, 95% CI −0.86 to 0.32, 
I2 = 0%). 
2. Range of motion 
Meta-analyses of two studies [43,44] showed that range of motion in flexion, abduc-
tion, internal and external rotation (Figure 9, SMD 0.23, 95% CI −0.07 to 0.52, I2 = 0%) was 
similar between the two groups. 
3. Mood state 
This sub-analysis of two trials [41,43] with 41 participants did not obtained statisti-
cally significant differences between groups (Figure 10, SMD −0.12, 95% CI −0.35 to 0.11, 
I2 = 0%). 
Low-quality evidence indicates that applying myofascial techniques does not have a 
greater immediate effect on pain intensity, range of motion in flexion, abduction, internal 
and external rotation, and mood state, than a placebo or a minimal intervention. For the 
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1. Pain Intensity
This sub-analysis included four trials [42–45] with 242 participants. No significant
differences were observed between the effects of myofascial therapy alone or in combination
with a standard physical therapy program and placebo intervention or a standard physical
therapy program (Figure 4. SMD −0.15, 95% CI −0.48 to 0.19, I2 = 28%).
2. Functionality
Meta-analyses of three studies [42,44,46] with 121 participants revealed that there
were no statistically significant differences between the two groups on post-immediate
functionality (Figure 5, SMD −0.17, 95% CI −0.43 to 0.09, I2 = 0%). However, the results
were in favor of the group treated with myofascial therapy.
3. Range of motion
This subgroup involved 3 trials [43–45] covering 95 participants. Meta-analysis result
demonstrated that myofascial therapy does not have a greater statistically significant im-
mediate effect on range of motion in flexion (Figure 6, SMD 0.30, 95% CI −0.13 to 0.74,
I2 = 11%) than a placebo treatment or other intervention. However, a statistically significant
result was o served for shoulder range of motion in abduction in favor of the experimental
group (Figure 7, SMD 0.46, 95% CI 0.05 to 0.87, I2 = 0%; p = 0.03)
Low-moderate quality evidence indicates that myofascial therapy does not have a
greater statistically significa t mmediate effect on pain intensity, functionality, and r nge
of motion in flexion than a placebo treatme t or other i tervention t post-immediate
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follow up. The estimations of the primary effect show small or null statistically significant
heterogeneity between the effect size of the studies included in this analysis; the statistic
I2 ranged from 0% “low threshold” and 28% “low-moderate threshold”.
3.8.2. Myofascial Therapy vs. Placebo Treatment or Minimal Intervention at
Post-Immediate
Figures 8–10 show the results of the estimated primary and secondary effects as
forest-plots grouped separately by outcome measure type, immediately following the
intervention with myofascial techniques.
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1. Pain intensity
Meta-analyses of two studies [43,44] with 45 participants, demonstrated that the effect
of myofascial therapy was no superior to placebo treatment nor minimal intervention for
alleviating post-immediate pain intensity (Figure 8, SMD−0.27, 95% CI−0.86 to 0.32, I2 = 0%).
2. Range of motion
Meta-analyses of two studies [43,44] showed that range of motion in flexion, abduction,
internal and external rotation (Figure 9, SMD 0.23, 95% CI −0.07 to 0.52, I2 = 0%) was
similar between the two groups.
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3. Mood state
This sub-analysis of two trials [41,43] with 41 participants did not obtained statistically
significant differences between groups (Figure 10, SMD −0.12, 95% CI −0.35 to 0.11, I2 = 0%).
Low-quality evidence indicates that applying myofascial techniques does not have a
greater immediate effect on pain intensity, range of motion in flexion, abduction, internal
and external rotation, and mood state, than a placebo or a minimal intervention. For the
three outcome measures, the I2 statistic was 0%, null statistic heterogeneity.
3.8.3. Myofascial Technique (Physical Therapy and Myofascial Therapy) vs. Other
Interventions (Physical Therapy and Placebo) at Post-Immediate, Medium Term and
Long Term
Figures 11–19 show the results as forest-plots grouped by primary and secondary effects,
and separated by the duration of the effects after completing the myofascial intervention.
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1. Pain Intensity
This meta-analysis included two studies and 197 participants [42,46]. The point
estimates for the SMD between the groups varied from 0.11 to 0.20 (Figures 11–13. 95% IC;
I2 = 0% to 71%) in the short-, medium-, and long-term; in all cases. The results of this
meta-analysis indicate that there is not a statistically significant effect for pain intensity in
favor of myofascial therapy over other types of interventions.
2. Functionality
Two studies with 197 participants were meta-analyzed for shoulder functionality [42,46].
The estimates varied from 0.15 to 0.19 (SMD) (Figures 14–16. 95% IC; I2 = 0%) and although
all of them favored the myofascial therapy, their differences were not statistically significant.
3. Quality of life
The result of the meta-analysis of two studies [42,46] demonstrated there were no
statistically significant differences between the two groups for quality of life at any time
(Figures 17–19), grouped estimates ranged from 0.03 to 0.15 (SMD) (95% IC; I2 = 22% to 73%).
Moderate-high quality evidence indicates that myofascial therapy has no greater
immediate, medium- and long-term effect on pain intensity, functionality, and quality of
life than other forms of intervention.
The grouped estimates show little statistical heterogeneity among the studies’ effect
sizes. Of the six comparisons of pain and disability, five showed a null I2 statistic, only
immediate post-treatment pain was above the ‘high’ threshold of 75%.
4. Discussion
4.1. Summary of Evidence
We set out to conduct a unique, up-to-date review on the impact of myofascial therapy
on breast cancer survivors. We found 8 published RCTs that evaluated the effects of
myofascial therapy on these patients, although two studies could not be meta-analyzed.
The study by Massingill et al. [47], could not be analyzed in the meta-analysis because
of incomplete data in the results, and that of Groef et al. [45], presented duplicate results
that were published in another of the studies included. Ultimately, for the qualitative
analysis, six publications were considered, including five studies (as those publications
by Fernández-Lao et al. [40,41] shared the same participants). Thus, a reduced number of
patients than previously mentioned, 262 participants total, were included.
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In general, we found that interventions with myofascial therapy as the sole interven-
tion or combined with physical therapy, do not generate, with low or moderate-quality
proof, a significant improvement on pain intensity, functionality, range of motion and mood
state in female survivors of breast cancer compared to an inactive control group or placebo
or in comparison with other interventions.
There were greater general effects in favor of myofascial therapy than other con-
trols/interventions, but the subgroup analyses revealed inconsistent, insignificant results.
Only the range of motion in abduction showed statistical significance in favor of the experi-
mental group. Here, myofascial therapy is at least equivalent to other forms of intervention.
Several factors should be considered when interpreting our findings for clinical rec-
ommendation and implementation. Although there was no statistical significance, all of
the studies individually reported a clinically relevant improvement in favor of the exper-
imental group with myofascial intervention. The effectiveness of myofascial therapy is
unclear because the subgroup analyses were hampered by the small number of studies
that included the same outcome measures and follow-up beyond immediately following
the intervention. Very few studies reported comparable estimates regarding secondary
outcome measures to calculate the effect of using myofascial therapy.
4.2. Agreements or Disagreements with Other Studies or Reviews
Myofascial therapy and its effect on certain populations has been briefly described in
literature. Other meta-analyses that have attempted to demonstrate the efficacy of myofas-
cial therapy have also faced the challenge of only finding articles of low methodological
quality, and as a result, a small number of articles are included in the meta-analysis. In
2016, Webb and colleagues [48] did not find conclusive results after their meta-analysis
about the efficacy of myofascial therapy on joint range of motion and perceived pain. A
recently-published article also obtained outcomes that tend towards the statistical signif-
icance of myofascial techniques for the improvement of joint range of motion, without
these generating a clinically relevant change [49]. Our article correlates with this article, as
obtaining statistical significance in the improvement of the range of motion in shoulder
abduction reaffirms myofascial therapy as an effective technique in the improvement of
this specific variable. Additionally, regarding survivors of breast cancer, other systematic
reviews have been carried out with meta-analyses using the generic term “manual ther-
apy”, which encompasses myofascial therapy. In the review carried out by Pinheiro and
colleagues (2019), manual therapy does prove to be effective to decrease musculoskeletal
pain [50]. However, this author could only include five articles in their meta-analysis,
again, due to the limiting characteristics of the trials carried on manual therapy and cancer.
These results are contradictory to those found in the review by Groef et al. (2015), that
when analyzing the effectiveness of various postoperative physical therapy modalities,
including myofascial therapy for the treatment of pain and range of motion of the shoul-
der in breast cancer, reported that to date, no RCT had reported on the effectiveness of
myofascial therapy started in the postoperative phase after breast cancer treatment [30].
Despite the differences found regarding pain, our findings showed no improvement using
myofascial therapy as opposed to other therapies on quality of life, which is consistent
with the findings obtained in the review by Pinheiro and colleagues (2019) [50].
Nevertheless, despite not obtaining clear, insightful results in recent years on the clini-
cal evidence of manual therapy and, thus, myofascial therapy, these techniques continue to
be prescribed as treatment for pain management in cancer patients [51], and also for ad-
dressing other symptoms such as anxiety or altered mood states, due to their non-invasive
nature and the absence of negative side effects. Myofascial therapy, described by Pilat in
2003 [52], is a relatively recent technique, which, despite its frequent use in clinical physical
therapy, has not been explored deeply or frequently enough to test its effects on different
populations. Thereby, as shown in this review, there are many different approaches of
myofascial therapy. In order to understand whether myofascial therapy is a useful rehabil-
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itation approach for this population, these differences should also be objective of future
randomized controlled trials, to check the superiority of specific methods among others.
5. Study Limitations
Our review was limited by the small number published trials to date, the impossi-
bility of blinding participants and physical therapists, the small sample size, and non-
homogeneous follow-up of the included studies.
The outcomes for pain intensity, functionality, and range of motion should be con-
sidered key to evaluating the effects of myofascial therapy on the study population, as
these factors are the main causes of the emotional burden of the disease [53]. Many of the
included studies did not report these results and, when reported, they were measured
at different time periods. The lack of standardization measurements makes quantitative
synthesis of the body of evidence problematic.
The inconsistent nature of data collection and reporting made it difficult to draw
conclusions regarding medium- and long-term results, as half of the studies only collected
data immediately following the intervention.
For example, in the comparison between myofascial therapy versus a placebo or
minimal intervention, the studies reported on the outcome measures of pain, range of
motion and mood state only immediately following treatment. The fact that this data was
not reported in a comparable manner over time limits our ability to estimate the true effect
of myofascial therapy on a critical outcome.
6. Conclusions
While our subgroup analyses show non-significance between groups, the results are
inconclusive. The choice of myofascial therapy over other control groups with/without
intervention for breast cancer survivors is likely to result in a positive effect on pain
intensity, functionality, and range of motion. Myofascial therapy is also likely to have a
beneficial effect on quality of life and mood state outcomes. However, given the results
obtained, it would seem that there is little to gain from referring these patients to myofascial
treatment. Despite this, the volume of evidence is small and additional similar studies are
likely to greatly change the estimation of the effectiveness of myofascial therapy versus
inactive controls, placebo, or other physical therapy interventions. Future studies are
needed to confirm whether myofascial therapy is useful or not to man-age breast cancer
survivors’ sequelae.
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